# Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

> **NCT01306929** · PHASE2 · COMPLETED · sponsor: **Prilenia** · enrollment: 134 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** pridopidine

## Key facts

- **NCT ID:** NCT01306929
- **Lead sponsor:** Prilenia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-24
- **Primary completion:** 2018-01-05
- **Final completion:** 2018-01-05
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01306929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01306929, "Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01306929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*